The dose after 0.5mg Wegovy isn't 2.4mg — here's the actual schedule

The biggest myth: that 0.5mg is just a brief formality before jumping to 2.4mg

A lot of people start Wegovy expecting to reach 2.4mg within a month or two, as if the earlier doses are little more than a warm-up. That's not quite how it works. The full titration from 0.25mg to 2.4mg spans a minimum of around 16 to 20 weeks when each step is held for the recommended four weeks. The 0.5mg phase is genuine medicine at a genuine dose, not a placeholder. Your body is responding to semaglutide throughout, appetite changes, gastric emptying slows, blood sugar regulation shifts. The steps exist so that those changes arrive gradually rather than all at once.

Skipping ahead, or assuming that 0.5mg should be escalated the moment you feel fine, can increase the likelihood of nausea, vomiting, or constipation. The NHS patient information for semaglutide confirms that the graduated schedule is an established part of how this medicine is managed. Moving to 1.0mg too soon is the kind of decision that a prescriber weighs carefully, not one to make independently.

If you're at 0.5mg and wondering what happens next, the short answer is: 1.0mg, after roughly four weeks, assuming your prescriber is satisfied with your tolerability and progress.

What 1.0mg means in practice, and the steps that follow it

Once you move to 1.0mg, you're entering the middle portion of the titration, not yet at the therapeutic maintenance dose, but no longer at the introductory end. Some people notice a more pronounced reduction in appetite at 1.0mg compared with 0.5mg; others find the difference subtle. Both are normal. After 1.0mg comes 1.7mg, and then the 2.4mg maintenance dose that most clinical trial evidence is built around.

It's worth knowing that 2.4mg is where the well-known results data sits. The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at 2.4mg semaglutide alongside lifestyle changes. The earlier doses are not designed to produce that level of effect on their own. They're preparation.

If you're curious about how the complete dosing pathway looks from start to maintenance, our overview of the full Wegovy dose range sets it out clearly. Some people also find it useful to understand the clinical considerations specific to moving from 0.5mg before their next review.

Why your prescriber might slow the pace, or occasionally hold a dose

The four-week interval is a minimum, not a maximum. If side effects are significant at any step, the right clinical call is often to hold that dose for longer rather than push ahead. This isn't a setback. Arriving at 2.4mg feeling well and tolerating the medicine properly is far more useful than rushing to the top dose and spending weeks managing persistent nausea.

Common side effects during titration are gastrointestinal: nausea tends to peak in the first few days after an increase, then ease. Constipation, indigestion, and occasional headaches are also reported. Staying hydrated and keeping meals smaller and lower in fat during the adjustment period helps most people through the steeper steps. If you've recently used your first injection and want to know what to expect from the device going forward, our guide to using the Wegovy pen after your first dose covers the practical details. A consistent injection day, same time each week, is one of the habits that makes the routine stick.

For context on what the cost of private treatment involves across the titration journey, our Wegovy treatment page sets out what's included. At nume, a prescriber personally reviews your progress before any dose change; the clinical review isn't automated. If side effects are bothering you between reviews, our support team is available seven days a week.

The newer 7.2mg dose and where it fits

You may have read that Wegovy now comes in a 7.2mg strength. That's accurate. The MHRA approved the dedicated single-dose 7.2mg pen on 14 April 2026, following earlier approval of the 7.2mg dose itself in January 2026. It's a higher maintenance option for adults with a BMI of 30 or above, reached only after the standard 2.4mg titration pathway, not a replacement for it. Trial data at 7.2mg reported average weight loss of around 20.7% over 72 weeks, bringing it closer to tirzepatide results. If you want to understand more about how Wegovy fits into the wider landscape of licensed weight-loss treatments in the UK, the treatment options overview is a useful starting point.

For people earlier in the journey (still at 0.25mg, for instance) the question of what follows the 0.25mg step comes up just as often. Our page on how the Wegovy pen works after two doses is helpful for anyone who wants to understand what the device and routine look like once those early injections are behind them. That structure is what separates supervised treatment from guesswork.